Organogenesis (ORGO) 10-Q 10 May 22 2022 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2022	May 01, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Document Transition Report	false
Entity Registrant Name	Organogenesis Holdings Inc.
Entity Central Index Key	0001661181
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Trading Symbol	ORGO
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Address, State or Province	MA
Title of 12(b) Security	Class A Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Entity Common Stock, Shares Outstanding		129,130,179
Entity File Number	001-37906
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	85 Dan Road
Entity Address, City or Town	Canton
Entity Address, Postal Zip Code	02021
Entity Tax Identification Number	98-1329150
City Area Code	781
Local Phone Number	575-0775

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 107,897	$ 113,929
Restricted cash	605	599
Accounts receivable, net	79,477	82,460
Inventory, net	22,737	25,022
Prepaid expenses and other current assets	7,135	4,969
Total current assets	217,851	226,979
Property and equipment, net	84,268	79,160
Intangible assets, net	24,452	25,673
Goodwill	28,772	28,772
Operating lease right-of-use assets, net	47,468	49,144
Deferred tax asset, net	31,994	31,994
Other assets	1,467	1,537
Total assets	436,272	443,259
Current liabilities:
Deferred acquisition consideration	1,436	1,436
Current portion of term loan	3,126	2,656
Finance lease obligations	101	200
Current portion of operating lease obligations	11,775	11,785
Accounts payable	27,935	29,339
Accrued expenses and other current liabilities	32,419	36,589
Total current liabilities	76,792	82,005
Term loan, net of current portion	69,869	70,769
Operating lease obligations, net of current portion	45,323	46,893
Other liabilities	1,060	1,557
Total liabilities	193,044	201,224
Commitments and contingencies (Note 18)
Stockholders' equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued
Common stock, $0.0001 par value; 400,000,000 shares authorized; 129,615,732 and 129,408,740 shares issued; 128,887,184 and 128,680,192 shares outstanding at March 31, 2022 and December 31, 2021, respectively.	13	13
Additional paid-in capital	303,261	302,155
Accumulated deficit	(60,046)	(60,133)
Total stockholders' equity	243,228	242,035
Total liabilities and stockholders' equity	$ 436,272	$ 443,259

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	129,615,732	129,408,740
Common stock, shares outstanding	128,887,184	128,680,192

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net revenue	$ 98,117	$ 102,552
Cost of goods sold	25,080	25,495
Gross profit	73,037	77,057
Operating expenses:
Selling, general and administrative	63,578	58,232
Research and development	8,587	6,209
Total operating expenses	72,165	64,441
Income from operations	872	12,616
Other expense, net:
Interest expense, net	(737)	(2,470)
Other expense, net	(3)	(3)
Total other expense, net	(740)	(2,473)
Net income before income taxes	132	10,143
Income tax expense	(45)	(200)
Net income	$ 87	$ 9,943
Net income, per share:
Basic	$ 0	$ 0.08
Diluted	$ 0	$ 0.07
Weighted-average common shares outstanding
Basic	128,788,721	127,870,065
Diluted	132,805,154	133,451,950

CONSOLIDATED STATEMENTS STOCKHO

CONSOLIDATED STATEMENTS STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Dec. 31, 2020	$ 141,808	$ 13	$ 296,830	$ (155,035)
Balance (in shares) at Dec. 31, 2020		127,731,833
Exercise of stock options	984		984
Exercise of stock options (in shares)		285,344
Vesting of RSUs, net of shares surrendered to pay taxes	(417)		(417)
Vesting of RSUs, net of shares surrendered to pay taxes (in shares)		85,078
Stock-based compensation expense	698		698
Net Income	9,943			9,943
Balance at Mar. 31, 2021	153,016	$ 13	298,095	(145,092)
Balance (in shares) at Mar. 31, 2021		128,102,255
Balance at Dec. 31, 2021	$ 242,035	$ 13	302,155	(60,133)
Balance (in shares) at Dec. 31, 2021	128,680,192	128,680,192
Exercise of stock options	$ 291		291
Exercise of stock options (in shares)		86,121
Vesting of RSUs, net of shares surrendered to pay taxes	(488)		(488)
Vesting of RSUs, net of shares surrendered to pay taxes (in shares)		120,871
Stock-based compensation expense	1,303		1,303
Net Income	87			87
Balance at Mar. 31, 2022	$ 243,228	$ 13	$ 303,261	$ (60,046)
Balance (in shares) at Mar. 31, 2022	128,887,184	128,887,184

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net income	$ 87	$ 9,943
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation	1,347	1,010
Amortization of intangible assets	1,221	1,243
Amortization of operating lease right-of-use assets	1,847	1,129
Non-cash interest expense	108	72
Deferred interest expense	151	525
Provision recorded for doubtful accounts	40	921
Loss on disposal of property and equipment	0	239
Adjustment for excess and obsolete inventories	2,205	2,290
Stock-based compensation	1,303	698
Change in fair value of Earnout liability	0	(296)
Changes in operating assets and liabilities:
Accounts receivable	2,942	(16,119)
Inventory	80	(4,212)
Prepaid expenses and other current assets	(2,165)	(622)
Operating leases	(1,751)	(1,210)
Accounts payable	(1,186)	1,842
Accrued expenses and other current liabilities	(4,828)	1,411
Other liabilities	10	(164)
Net cash provided by (used in) operating activities	1,411	(1,300)
Cash flows from investing activities:
Purchases of property and equipment	(6,672)	(4,957)
Net cash used in investing activities	(6,672)	(4,957)
Cash flows from financing activities:
Payments of term loan	(469)	0
Payments of withholding taxes in connection with RSUs vesting	(488)	(417)
Proceeds from the exercise of stock options	291	984
Principal repayments of finance lease obligations	(99)	(675)
Payment of deferred acquisition consideration	0	(483)
Net cash used in financing activities	(765)	(591)
Change in cash, cash equivalents, and restricted cash	(6,026)	(6,848)
Cash, cash equivalents, and restricted cash, beginning of period	114,528	84,806
Cash, cash equivalents, and restricted cash, end of period	108,502	77,958
Supplemental disclosure of cash flow information:
Cash paid for interest	627	1,937
Cash paid for income taxes	4	0
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses	1,869	306
Right-of-use assets obtained through operating lease obligations	$ 171	$ 310

Nature of Business and Basis of

Nature of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	1. Nature of Business and Basis of Presentation Organogenesis Holdings Inc. (formerly Avista Healthcare Public Acquisition Corp.) (“ORGO” or the “Company”) is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Several of the existing and pipeline products in the Company’s portfolio have Premarket Application (“PMA”) approval, or Premarket Notification 510(k) clearance from the United States Food and Drug Administration (“FDA”). The Company’s customers include hospitals, wound care centers, government facilities, ambulatory service centers (“ASCs”) and physician offices. The Company has one operating and reportable segment. COVID-19 The coronavirus (COVID-19) COVID-19 COVID-19 The Company is closely monitoring the evolving impact of the pandemic on all aspects of its business. The Company has implemented a number of measures designed to protect the health and safety of its employees, support its customers and promote business continuity.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note “2. Significant Accounting Policies” to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K Unaudited Interim Financial Information The accompanying unaudited consolidated financial statements have been prepared by management in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. While we believe that the disclosures presented are adequate in order to make the information not misleading, these unaudited quarterly financial statements should be read in conjunction with the financial statements and notes thereto included in the Annual Report. The unaudited consolidated financial statements include the accounts and results of operations of Organogenesis Holdings Inc. and its wholly-owned subsidiaries of Organogenesis Inc., including Organogenesis GmbH (a Switzerland corporation) and Prime Merger Sub, LLC. All intercompany balances and transactions have been eliminated in consolidation. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. In the opinion of management, the unaudited consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s financial position, results of operations and cash flows at the dates and for the periods indicated. The results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future years or periods. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported results of operations during the reporting periods. In preparing the consolidated financial statements, the estimates and assumptions that management consider to be significant and that present the greatest amount of uncertainty include: revenue recognition; sales returns and credit losses; inventory reserve; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite lived assets (including intangible assets); assessing impairment of goodwill; valuation of assets and liabilities that use unobservable inputs; and the valuation and recognition of stock-based compensation. Actual results and outcomes may differ significantly from those estimates and assumptions. Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2019-12, Income Taxes— Simplifying the Accounting for Income Taxes 2019-12 Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13 , Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Subsequent ASU 2016-13, the ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments- Credit Losses ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ASU 2019-05, Financial Instruments—Credit Losses (Topic 326)—Targeted Transition Relief ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses ASU 2016-13 and ASU 2016-13 and ASU 2016-13 In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting 2020-04”). 2020-04 No. 2021-01, Reference Rate Reform (Topic 848): Scope 2021-01”), 2020-04 2021-01 2020-04 2021-01

Acquisition

Acquisition	3 Months Ended
	Mar. 31, 2022
Business Combinations [Abstract]
Acquisition	3. Acquisition On September 17, 2020 (the “Acquisition Date”), the Company acquired certain assets and assumed certain liabilities of CPN Biosciences, LLC (“CPN”) pursuant to an asset purchase agreement dated July 24, 2020. CPN offered a physician office management solution and advanced wound care products. The aggregate consideration amounted to $19,024 as of the Acquisition Date, consisting of $6,427 in cash, 2,151,438 shares of the Company’s Class A common stock with a fair value of $8,815, and contingent consideration (the “Earnout”) with a fair value of $3,782. On the Acquisition Date, the Company paid $5,820 in cash and issued 1,947,953 shares of the Company’s Class A common stock. The remaining consideration of $1,436 was held back and was released in April 2022 by the Company paying additional $739 in cash and issuing additional 203,485 shares of the Company’s Class A common stock to the former equityholders The Company is obligated to pay the Earnout to CPN’s former equityholders non-current Assets and Liabilities”.

Product and Geographic Sales

Product and Geographic Sales	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Product and Geographic Sales	4. Product and Geographic Sales The Company generates revenue through the sale of Advanced Wound Care and Surgical & Sports Medicine products. There is a single performance obligation in all of the Company’s contracts, which is the Company’s promise to transfer the Company’s products to customers based on specific payment and shipping terms in the arrangement. The entire transaction price reflects a single performance obligation. Product revenue is recognized when a customer obtains control of the Company’s products which occurs at a point in time and may be upon shipment, procedure date, or delivery, based on the terms of the contract. Revenue is recorded net of a reserve for returns, discounts , The following tables set forth revenue by product category: Three Months Ended March 31, 2022 2021 Advanced Wound Care $ 90,950 $ 90,708 Surgical & Sports Medicine 7,167 11,844 Total net revenue $ 98,117 $ 102,552 For all periods presented, net revenue generated outside the United States represented less than 1% of total net revenue.

Fair Value Measurement of Finan

Fair Value Measurement of Financial Assets and Liabilities	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement of Financial Assets and Liabilities	5. Fair Value Measurement As of March 31, 2022 and December 31, 2021, the Company’s financial assets and liabilities measured at fair value on a recurring basis only included the Earnout liability as discussed below. Earnout Liability In connection with accounting for the CPN acquisition on September 17, 2020, the Company recorded an Earnout liability of $3,782 on the Acquisition Date, representing the fair value of contingent consideration payable upon the achievement of a certain revenue target. The Earnout liability is classified as a Level 3 measurement within the fair value hierarchy for which fair value is derived from inputs that are unobservable and significant to the overall fair value measurement. The fair value of such Earnout liability is estimated using a Monte Carlo simulation model that utilizes key assumptions including forecasted revenues and volatilities of the underlying financial metrics during the Earnout Period. The Company assesses the fair value of the Earnout liability at each reporting period. Any subsequent changes in the estimated fair value of the liability are reflected in selling, general and administrative expenses until the liability is settled. For more information about the Earnout liability, refer to Note “3. Acquisition”. As of December 31, 2021 and March 31, 2022, the Earnout liability was $0 as a result of the Company’s updated assessment of the near-term market for the CPN product portfolio. The following table provides a roll-forward of the fair value of the Company’s Earnout liability, for which fair value is determined using Level 3 inputs: Three Months Ended March 31, 2022 2021 Beginning balance $ — $ 3,985 Change in fair value — (296 ) Ending balance $ — $ 3,689 The Company did not have any financial assets a nd non-recurring

Accounts Receivable, Net

Accounts Receivable, Net	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Accounts Receivable, Net	6. Accounts Receivable, Net Accounts receivable consisted of the following: March 31 December 31, 2022 2021 Accounts receivable $ 84,604 $ 87,613 Less — allowance for doubtful accounts (5,127 ) (5,153 ) $ 79,477 $ 82,460 The Company’s allowance for doubtful accounts was comprised of the following: Three Months Ended March 31, 2022 2021 Balance at beginning of period $ 5,153 $ 2,669 Additions 40 921 Write-offs (66 ) (14 ) Balance at end of period $ 5,127 $ 3,576

Inventories

Inventories	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Inventories	7. Inventories Inventories, net of related reserves for excess and obsolescence, consisted of the following: March 31, December 31, 2022 2021 Raw materials $ 9,524 $ 9,023 Work in process 995 991 Finished goods 12,218 15,008 $ 22,737 $ 25,022 Raw materials include various components used in the Company’s manufacturing process. The Company’s excess and obsolete inventory review process includes analysis of sales forecasts and historical sales as compared to inventory level and working with operations to maximize recovery of excess inventory. During the three months ended March 31, 2022 and 2021, the Company charged $2,205 and $2,290, respectively, for inventory excess and obsolescence to cost of goods sold within the consolidated statements of operations.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Prepaid Expenses and Other Current Assets	8. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following: March 31, 2022 December 31, 2021 Subscriptions $ 2,685 $ 2,745 Conferences and marketing expenses 2,060 538 Deposits 1,344 1,216 Insurance 1,001 358 Other 45 112 $ 7,135 $ 4,969 Deposits are funds held by vendors which are expected to be released within twelve months and therefore they are recorded as current assets.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	9. Property and Equipment, Net Property and equipment consisted of the following: March 31, December 31, Leasehold improvements $ 33,973 $ 30,531 Buildings 4,943 4,943 Furniture, computers and equipment 54,822 53,959 93,738 89,433 Accumulated depreciation and amortization (59,075 ) (57,729 ) Construction in progress 49,605 47,456 $ 84,268 $ 79,160 Depreciation expense was $1,347 and $1,010, for the three months ended March 31, 2022 and 2021, respectively. Construction in progress primarily represents unfinished c ons

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	10. Goodwill and Intangible Assets Goodwill was $28,772 as of March 31, 2022 and December 31, 2021. Identifiable intangible assets consisted of the following as of March 31, 2022: Original Accumulated Net Book Developed technology $ 32,620 $ (18,573 ) $ 14,047 Trade names and trademarks 2,080 (1,236 ) 844 Customer relationships 10,690 (1,648 ) 9,042 Independent sales agency network 4,500 (4,500 ) — Patent 7,623 (7,623 ) — Non-compete 1,010 (491 ) 519 Total $ 58,523 $ (34,071 ) $ 24,452 Identifiable intangible assets consisted of the following as of December 31, 2021: Original Accumulated Net Book Developed technology $ 32,620 $ (17,709 ) $ 14,911 Trade names and trademarks 2,080 (1,183 ) 897 Customer relationship 10,690 (1,381 ) 9,309 Independent sales agency network 4,500 (4,500 ) — Patent 7,623 (7,623 ) — Non-compete 1,010 (454 ) 556 Total $ 58,523 $ (32,850 ) $ 25,673 Amortization of intangible assets, calculated on a straight-line basis or using an accelerated method, was $1,221 and $1,243 for the three months ended March 31, 2022 and 2021, respectively.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	11. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: March 31, December 31, Personnel costs $ 23,060 $ 26,865 Royalties 3,190 3,458 Accrued but unpaid lease obligations and interest 3,981 3,963 Other 2,188 2,303 $ 32,419 $ 36,589 The accrued but unpaid lease obligations and the interest accrual on these obligations are related to the buildings in Canton, Massachusetts. See Note “17. Leases”.

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring	12. Restructuring In order to reduce the Company’s cost structure and achieve operating efficiency, the Company is consolidating its manufacturing operations in various locations into Massachusetts facilities. On October 21, 2020, the Company committed to a plan to restructure the workforce and operations in its La Jolla, California facilities. The restructuring involved approximately On March 9, 2022, the Company committed to million is related to the other exit activities, including but not limited to contract termination, decommission and transportation of certain fixed assets. As employees are required to provide future services, employee retention and other benefit-related costs are expensed over the service period. As a result of the restructuring activities, the Company incurred a pre-tax charge Employee Other Total Liability balance as of December 31, 2021 $ 2,517 $ 651 $ Expenses 115 149 264 Payments (2,517 ) (783 ) (3,300 ) Liability balance as of March 31, 2022 $ 115 $ 17 $ 132

Long-Term Debt Obligations

Long-Term Debt Obligations	3 Months Ended
	Mar. 31, 2022
Long-term Debt, Unclassified [Abstract]
Long-Term Debt Obligations	13. Long-Term Debt Obligations Long-term debt obligations consisted of the following: March 31, December 31, Line of credit $ — $ — Term loan 73,593 74,062 Less debt discount and debt issuance cost (598 ) (637 ) Term loan, net of debt discount, debt issuance cost $ 72,995 $ 73,425 2021 Credit Agreement In August 2021, the Company, as borrower, its subsidiaries, as guarantors, and Silicon Valley Bank (“SVB”), and the several other lenders thereto (collectively, the “Lenders”) entered into a credit agreement (the “2021 Credit Agreement”), providing for a term loan facility not to exceed $75,000 (the “Term Loan Facility”) and a revolving credit facility not to exceed $125,000 (the “Revolving Facility”). The Company’s obligations to the Lenders are secured by substantially all of the Company’s assets, including intellectual property. Capitalized terms used herein and not otherwise defined are defined as set forth in the 2021 Credit Agreement. Advances plus The 2021 Credit Agreement requires the Company to make consecutive quarterly installment payments equal to the following: (a) from September 30, 2021 through and including June 30, 2022, $469; (b) from September 30, 2022 through and including June 30, 2023, $938; (c) from September 30, 2023 through and including June 30, 2025, $1,406 and (d) from September 30, 2025 and the last day of each quarter thereafter until August 6, 2026 (the “Term Loan Maturity Date”), $1,875. The Company may prepay the Term Loan Facility, provided that any Term Loans prepaid prior to August 6, 2022 must be accompanied by a prepayment premium equal to 1.00% of the aggregate amount of Term Loans prepaid. Once repaid, amounts borrowed under the Term Loan Facility may not be re-borrowed. The Company must pay in arrears, on the first day of each quarter prior to August 6, 2026 (the “Revolving Termination Date”) and on the Revolving Termination Date, a fee for the Company’s non-use of Under the 2021 Credit Agreement, the Company is required to comply with certain financial covenants including the Consolidated Fixed Charge Coverage Ratio and Consolidated Total Net Leverage Ratio, tested quarterly. In addition, the Company is also required to make representations and warranties and comply with certain non-financial The Company had outstanding borrowings of $73,593 and $74,062 under the Term Loan Facility and $0 under the Revolving Facility with $125,000 available for future revolving borrowings as of March 31, 2022 and December 31, 2021, respectively. The Company recorded additional debt issuance costs and related fees of $604 in connection with the Term Loan Facility, which are recorded as a reduction of the carrying value of the term loan on the Company’s consolidated balance sheets. In connection with the Revolving Facility, the Company recorded debt issuance costs and related fees of $1,223, which are recorded as other assets. Both of these costs are being amortized to interest expense through the maturity date of the facilities. Future payments of the 2021 Credit Agreement, as of March 31, 2022, are as follows for the calendar years ending December 31: 2022 $ 2,343 2023 4,687 2024 5,625 2025 6,563 2026 54,375 Total $ 73,593 2019 Credit Agreement In March 2019, the Company, its subsidiaries and SVB, and the several other lenders thereto entered into a credit agreement, as amended (the “2019 Credit Agreement”), providing for a term loan facility of $40,000 and a revolving credit facility of up to $60,000. Both facilities were set to mature in 2024. The interest rate for the term loan facility was a floating per annum interest rate equal to the greater of 3.75% above the Wall Street Journal Prime Rate and 9.25%. The interest rate for advances under the revolving facility was a floating per annum interest rate equal to the greater of the Wall Street Journal Prime Rate and 5.50%. If the Company elected to prepay the loan or terminate the facilities, the Company was required to pay a certain percentage of the outstanding principal as a prepayment fee. A final payment fee (the “Final Payment”) of 6.5% multiplied by the original aggregate principal amount of term loan facility was due upon the earlier to occur of the maturity date of the term loan or prepayment of all outstanding principal . In August 2021, upon entering into the 2021 Credit Agreement, the Company paid an aggregate amount of $70,559 due under the 2019 Credit Agreement, including unpaid principal, accrued interest, the Final Payment and a prepayment fee, with proceeds from the 2021 Credit Agreement, and the 2019 Credit Agreement was terminated. Upon termination of the 2019 Credit Agreement, the Company recognized $1,883 as loss on the extinguishment of the loan for the year ended December 31, 2021.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Stockholders' Equity	14. Stockholders’ Equity Common Stock As of March 31, 2022, t As of March 31, 2022 and December 31, 2021, the Company reserved the following shares of Class A common stock for future issuance: March 31 December 31, Shares reserved for issuance for outstanding options 7,924,792 6,596,969 Shares reserved for issuance for outstanding restricted stock units 1,496,853 764,871 Shares reserved for issuance for future grants 3,373,334 5,644,691 Total shares of authorized common stock reserved for future issuance 12,794,979 13,006,531

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	15. Stock-Based Compensation Stock Incentive Plans-the On November 28, 2018, the Board of Directors of the Company adopted, and on December 10, 2018 the Company’s stockholders approved, the Organogenesis 2018 Equity and Incentive Plan (the “2018 Plan”). The purposes of the 2018 Plan are to provide long-term incentives and rewards to the Company’s employees, officers, directors and other key persons (including consultants), to attract and retain persons with the requisite experience and ability, and to more closely align the interests of such employees, officers, directors and other key persons with the interests of the Company’s stockholders. The 2018 Plan authorizes the Company’s Board of Directors or a committee of not less than two independent directors (in either case, the “Administrator”) to grant the following types of awards: non-statutory A total of shares of Class A common stock have been authorized to be issued under the 2018 Plan (subject to adjustment in the case of any stock dividend, stock split, reverse stock split, or similar change in capitalization of the Company). There has been no change to the total authorized shares since the adoption of the 2018 Plan. Stock Incentive Plans-the The Organogenesis 2003 Stock Incentive Plan (the “2003 Plan”), provides for the Company to issue restricted stock awards, or to grant incentive stock options or non-statutory non-statutory Effective as of the closing of the Avista Merger on December 10, 2018, no additional awards may be made under the 2003 Plan and as a result (i) any shares in respect of stock options that are expired or terminated under the 2003 Plan without having been fully exercised will not be available for future awards; (ii) any shares in respect of restricted stock that are forfeited to, or otherwise repurchased by the Company, will not be available for future awards; and (iii) any shares of Class A common stock that are tendered to the Company by a participant to exercise an award will not be available for future awards. Stock-Based Compensation Expense Stock options awarded under the stock incentive plans expire 10 years after the grant date and typically vest over four Stock-based compensation expense was $1,303 and $698 for the three months ended March 31, 2022 and 2021, respectively. The total amount of stock-based compensation expense was included within selling, general and administrative expenses on the consolidated statements of operations. Restricted Stock Units (RSUs) The Company granted 931,431 and 284,708 time-based restricted stock units to its employees, executives and the Board of Directors in the three months ended March 31, 2022 and 2021, respectively. Each restricted stock unit represents the contingent right to receive one share of the Company’s Class A common stock. A majority of the restricted stock units will vest in four equal annual installments. The fair value of the restricted stock units was based on the fair market value of the Company’s stock on the date of grant. The activity of restricted stock units is set forth below: Number of Weighted Unvested at December 31, 2021 764,871 $ 7.52 Granted 931,431 7.59 Vested (179,714 ) 7.81 Canceled/Forfeited (19,735 ) 6.83 Unvested at March 31, 2022 1,496,853 $ 7.54 As of March 31, 2022, the total unrecognized compensation cost related to unvested restricted stock units expected to vest was $7,892 and the weighted average remaining recognition period for unvested awards was 3.19 years. Stock Option Valuation The stock options granted during the three months ended March 31, 2022 and 2021 were 1,418,224 and 1,037,099, respectively. The assumptions that the Company used to determine the grant-date fair value of stock options granted during these periods were as follows, presented on a weighted-average basis: Three Months Ended March 31, 2022 2021 Risk-free interest rate 1.92 % 0.82 % Expected term (in years) 6.25 6.21 Expected volatility 50.66 % 39.30 % Expected dividend yield 0.0 % 0.0 % Exercise price $ 8.03 $ 13.54 Underlying stock price $ 7.87 $ 13.54 These assumptions resulted in an estimated weighted-average grant-date fair value per share of stock options granted during the three months ended March 31, 2022 and 2021 of $3.94 and $5.31, respectively. Stock Option Activity The following table summarizes the Company’s stock option activity since December 31, 2021: Number of Weighted Weighted (in years) Aggregate Outstanding as of December 31, 2021 6,596,969 $ 4.10 5.20 $ 38,524 Granted 1,418,224 8.03 Exercised (86,121 ) 3.38 441 Canceled / forfeited (4,280 ) 2.69 Outstanding as of March 31, 2022 7,924,792 4.82 5.83 29,053 Options exercisable as of March 31, 2022 4,600,567 2.52 3.57 25,113 Options vested or expected to vest as of March 31, 2022 7,215,073 $ 4.44 5.50 $ 28,567 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s Class A common stock for those stock options that have exercise prices lower than the fair value of the Company’s Class A common stock. The total fair value of options vested during the three months ended March 31, 2022 and 2021 was $1,612 and $143, respectively. As of March 31, 2022, the total unrecognized stock compensation expense related to unvested stock options expected to vest was $7,579 and was expected to be recognized over a weighted-average period of 3.29 years.

Net Income (Loss) Per Share (EP

Net Income (Loss) Per Share (EPS)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Income (Loss) per Share (EPS)	16. Net Income per Share (EPS) Basic EPS is calculated by dividing net income (loss) by the weighted-average number of shares outstanding during the period. Diluted EPS is calculated by dividing net income (loss) by the weighted-average number of shares outstanding plus the dilutive effect, if any, of outstanding equity awards using the treasury stock method which includes consideration of unrecognized compensation expenses as additional proceeds. A reconciliation of the numerator and denomina to Three Months Ended March 31, 2022 2021 Numerator: Net Income $ 87 $ 9,943 Denominator: Weighted average common shares outstanding —basic 128,788,721 127,870,065 Dilutive effect of restricted stock units 264,075 527,658 Dilutive effect of options 3,752,358 5,054,227 Weighted-average common shares outstanding—diluted 132,805,154 133,451,950 Earnings per share—basic $ 0.00 $ 0.08 Earnings per share—diluted $ 0.00 $ 0.07 For the three months ended March 31, 2022 and 20

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	17. Leases As of December 31, 2021 and March 31, 2022, the Company’s contracts that contained a lease consisted primarily of real estate, equipment and vehicle leases. The Company leases real estate for office, lab, warehouse and production space under noncancelable leases that expire at various dates through 2035, subject to the Company’s options to terminate or renew certain leases for an additional five The Company leases vehicles under operating leases for certain employees and has fleet services agreements for service on these vehicles. The minimum lease term for each newly leased vehicle is 367 days with renewal options. The Company may terminate the vehicle lease after the minimum lease term upon thirty days’ prior notice. The Company also leases other equipment under noncancelable operating and finance leases that expire at various dates through 2025. The Company determines if an arrangement is a lease at lease inception. The options to extend or terminate a lease are included in the lease terms when it is reasonably certain that the Company will exercise the options. Operating leases are included in operating lease right-of-use right-of-use Right-of-use Right-of-use right-of-use The Company records rent expense for its operating leases on a straight-line basis from the lease commencement date until the end of the lease term. The Company records finance lease cost as a combination of the depreciation expense for the right-of-use right-of-use On January 1, 2013, the Company entered into finance lease arrangements with 65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC and 275 Dan Road SPE, LLC for office and laboratory space in Canton, Massachusetts. 65 Dan Road SPE, LLC, 85 Dan Road Associates, LLC, Dan Road Equity I, LLC and 275 Dan Road SPE, LLC are related parties as the owners of these entities are also stockholders of the Company. Other than the lease with 275 Dan Road SPE, LLC which was terminated in August 2021 as discussed below, the remaining three leases were set to terminate on December 31, 2022 and each contained a renewal option for a five-year period with a rental rate at the greater of (i) rent for the last year of the prior term, or (ii) the then fair market value. The Company exercised the option to extend the leases for an additional five years in November 2021. These leases were reclassified from finance leases to operating leases upon the Company’s reassessment of the lease classification according to ASC 842-10-25-1 Lease Classification. lease right-of-use assets As of December 31, 2020, the Company owed an aggregate of $10,336 of accrued but unpaid lease obligations under the aforementioned leases. Effective April 1, 2019, the Company agreed to accrue interest on the accrued but unpaid lease obligations at an interest rate equal to the rate charged in the 2019 Credit Agreement. These accrued but unpaid lease obligations as well as the accrued interest on these obligations were subordinated to the 2019 Credit Agreement. With the termination of the 2019 Credit Agreement and the execution of the 2021 Credit Agreement (see Note “13. Long-Term Debt Obligations”) in August 2021, these obligations are no longer subordinated to the Company’s existing loans. In 842-20-40-2 Purchase of the Underlying Asset The accrued but unpaid lease obligations as well as the related interest accruals are shown below. March 31 December 31, 2022 2021 Principal portion of rent in arrears 7,246 7,246 Unpaid operating and common area maintenance costs 52 558 Total accrued but unpaid lease obligations 7,298 7,804 Accrued interest on accrued but unpaid lease obligations 1,956 1,938 The principal portion of rent in arrears was included in the short-term portion of operating lease obligations other than the balance related to the 275 Dan Road Building that was included in accrued expenses and other current liabilities on the consolidated balance sheets as of March 31, 2022 and December 31, 2021. The unpaid operating and common area maintenance costs, and the accrued interest on the accrued but unpaid lease obligations were included in accrued expenses and other current liabilities on the consolidated balance sheets as of March 31, 2022 and December 31, 2021 . The components of lease cost were as follows: Three Months Ended March 31, Classification 2022 2021 Finance lease Amortization of right-of-use COGS and SG&A $ 107 $ 299 Interest on lease liabilities Interest Expense 5 349 Total Finance lease cost 112 648 Operating lease cost COGS, R&D, SG&A 2,434 1,280 Short-term lease cost COGS, R&D, SG&A 669 715 Variable lease cost COGS, R&D, SG&A 918 1,363 Total lease cost $ 4,133 $ 4,006 Supplemental balance sheet information related to finance leases was as follows: March 31, 2022 December 31, Property and equipment, gross $ 1,174 $ 1,174 Accumulated depreciation (1,067 ) (961 ) Property $ 107 $ 213 Finance lease obligations $ 101 $ 200 Supplemental cash flow information related to leases was as follows: Three Months Ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 2,337 $ 1,362 Operating cash flows for finance leases $ 5 $ 523 Financing cash flows for finance leases $ 99 $ 675 Right-of-use Operating leases $ 171 $ 310 Finance leases $ — $ — March 31, December 31, Weighted-average remaining lease term Finance leases 0.21 0.45 Operating leases 8.04 8.22 March 31, December 31, Weighted-average discount rate Finance leases 11.30 % 11.30 % Operating leases 4.53 % 4.51 % As of March 31, 2021, maturities of lease liabilities were as follows: Operating leases Finance leases 2022 $ 11,873 $ 103 2023 8,104 — 2024 7,315 — 2025 7,526 — 2026 7,435 — Thereafter 25,966 — Total lease payments 68,219 103 Less: interest (11,121 ) (2 ) Total lease liabilities $ 57,098 $ 101

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure	18. Commitments and Contingencies Royalties The Company entered into a license agreement with a university for certain patent rights related to the development, use and production of one of its advanced wound care products. Under this agreement, the Company incurred a royalty based on a percentage of net product sales, for the use of these patents until the patents expired, which was in November 2006. Accrued royalties totaled $1,187 as of March 31, 2022 and December 31, 2021, respectively, and were classified as part of accrued expenses and other current liabilities on the Company’s consolidated balance sheets. There was no royalty expense incurred during the three months ended March 31, 2022 or 2021 related to this agreement. In October 2017, the Company entered into a license agreement with a third party. Under the license agreement, the Company is required to pay royalties based on a percentage of net sales of the licensed product that occur, after December 31, 2017, through the expiration of the underlying patent in October 2026, subject to minimum royalty payment provisions. The Company recorded royalty expense of $1,601 and $1,220 during the three months ended March 31, 2022 and 2021, respectively, within selling, general and administrative expenses on the consolidated statements of operations. Legal Matters In conducting its activities, the Company, from time to time, is subject to various claims and also has claims against others. In management’s opinion, the ultimate resolution of such claims would not have a material effect on the financial position, operating results or cash flows of the Company. The Company accrues for these claims when amounts due are probable and estimable. The Company accrued $150 as of March 31, 2022 and December 31, 2021 in relation to certain pending lawsuits.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	19. Related Party Transactions Lease obligations to affiliates, including accrued but unpaid lease obligations, and purchase of an asset under a finance lease with an affiliate are further described in Note “17. Leases”. During 2010, the Company’s Board of Directors approved a loan program that permitted the Company to make loans to three executives of the Company (the “Employer Loans”) to (i) provide them with liquidity (“Liquidity Loans”) and (ii) fund the exercise of vested stock options (“Option Loans”). Two of the executives left the Company in 2014. The Employer Loans matured with all principal and accrued interest due on the tenth anniversary of the issuance date of each subject loan. Interest on the Employer Loans was at various rates ranging from 2.30 % -

Taxes

Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Taxes	20. Taxes The Company is principally subject to taxation in the United States. The Company has a history of net operating losses both federally and in various states and began utilizing those losses to offset current taxable income in 2020. The Company’s wholly owned Swiss subsidiary, Organogenesis Switzerland GmbH, is subject to taxation in Switzerland and has a transfer pricing arrangement in place with Organogenesis Inc., its U.S. parent and a wholly owned subsidiary of the Company. The income tax rate for the three months ended March 31, 2022 varied from the U.S. statutory rate of 21% primarily due to the tax adjustments related to executive compensation, other permanent tax adjustments, and discrete items. Income tax expense for the three months ended March 31, 2022 was $45, which include d , and related primarily to federal and state taxes. Income tax expense for the three months ended March 31, 2021 was The Company examines all positive and negative evidence to estimate whether sufficient future taxable income in the U.S. will be generated to permit the use of existing deferred tax assets. In the fourth quarter of 2021, the Company released the valuation allowance recorded against its U.S. deferred tax assets. Upon reviewing the positive evidence of net operating loss utilization, cumulative profits, and forecasted taxable income, the Company believed that it was more likely than not that these United States deferred tax assets will be utilized. There are no material deferred tax assets in the other jurisdictions. On a quarterly basis, the Company reassesses the need for a valuation allowance on deferred income tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets. After assessing both the positive and negative evidence, including net operating loss utilization, cumulative profits, and forecasted taxable income, the Company determined that it is more likely than not the U.S. deferred assets will be realized in full. As such, the Company has not recorded a valuation allowance against its U.S. deferred tax assets as of March 31, 2022 and December 31, 2021.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	21. Subsequent Events The Company has evaluated subsequent events through May 10, 2022, the date on which these consolidated financial statements were issued and has determined that there were no such events to report.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited consolidated financial statements have been prepared by management in accordance with GAAP and the rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. While we believe that the disclosures presented are adequate in order to make the information not misleading, these unaudited quarterly financial statements should be read in conjunction with the financial statements and notes thereto included in the Annual Report. The unaudited consolidated financial statements include the accounts and results of operations of Organogenesis Holdings Inc. and its wholly-owned subsidiaries of Organogenesis Inc., including Organogenesis GmbH (a Switzerland corporation) and Prime Merger Sub, LLC. All intercompany balances and transactions have been eliminated in consolidation. The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. In the opinion of management, the unaudited consolidated financial statements reflect all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s financial position, results of operations and cash flows at the dates and for the periods indicated. The results for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future years or periods.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported results of operations during the reporting periods. In preparing the consolidated financial statements, the estimates and assumptions that management consider to be significant and that present the greatest amount of uncertainty include: revenue recognition; sales returns and credit losses; inventory reserve; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite lived assets (including intangible assets); assessing impairment of goodwill; valuation of assets and liabilities that use unobservable inputs; and the valuation and recognition of stock-based compensation. Actual results and outcomes may differ significantly from those estimates and assumptions.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2019-12, Income Taxes— Simplifying the Accounting for Income Taxes 2019-12
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13 , Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). Subsequent ASU 2016-13, the ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments- Credit Losses ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments ASU 2019-05, Financial Instruments—Credit Losses (Topic 326)—Targeted Transition Relief ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses ASU 2016-13 and ASU 2016-13 and ASU 2016-13 In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting 2020-04”). 2020-04 No. 2021-01, Reference Rate Reform (Topic 848): Scope 2021-01”), 2020-04 2021-01 2020-04 2021-01

Product and Geographic Sales (T

Product and Geographic Sales (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Reporting [Abstract]
Schedule of Revenue by Product Category	The following tables set forth revenue by product category: Three Months Ended March 31, 2022 2021 Advanced Wound Care $ 90,950 $ 90,708 Surgical & Sports Medicine 7,167 11,844 Total net revenue $ 98,117 $ 102,552

Fair Value Measurement of Fin_2

Fair Value Measurement of Financial Assets and Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Summary of Fair Value of Earnout liability	The following table provides a roll-forward of the fair value of the Company’s Earnout liability, for which fair value is determined using Level 3 Three Months Ended March 31, 2022 2021 Beginning balance $ — $ 3,985 Change in fair value — (296 ) Ending balance $ — $ 3,689

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
Schedule of accounts receivable	Accounts receivable consisted of the following: March 31 December 31, 2022 2021 Accounts receivable $ 84,604 $ 87,613 Less — allowance for doubtful accounts (5,127 ) (5,153 ) $ 79,477 $ 82,460
Schedule of allowance for doubtful accounts	The Company’s allowance for doubtful accounts was comprised of the following: Three Months Ended March 31, 2022 2021 Balance at beginning of period $ 5,153 $ 2,669 Additions 40 921 Write-offs (66 ) (14 ) Balance at end of period $ 5,127 $ 3,576

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories, net of related reserves for excess and obsolescence, consisted of the following: March 31, December 31, 2022 2021 Raw materials $ 9,524 $ 9,023 Work in process 995 991 Finished goods 12,218 15,008 $ 22,737 $ 25,022

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consisted of the following: March 31, 2022 December 31, 2021 Subscriptions $ 2,685 $ 2,745 Conferences and marketing expenses 2,060 538 Deposits 1,344 1,216 Insurance 1,001 358 Other 45 112 $ 7,135 $ 4,969

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and equipment consisted of the following: March 31, December 31, Leasehold improvements $ 33,973 $ 30,531 Buildings 4,943 4,943 Furniture, computers and equipment 54,822 53,959 93,738 89,433 Accumulated depreciation and amortization (59,075 ) (57,729 ) Construction in progress 49,605 47,456 $ 84,268 $ 79,160

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Identifiable intangible assets consisted of the following as of March 31, 2022: Original Accumulated Net Book Developed technology $ 32,620 $ (18,573 ) $ 14,047 Trade names and trademarks 2,080 (1,236 ) 844 Customer relationships 10,690 (1,648 ) 9,042 Independent sales agency network 4,500 (4,500 ) — Patent 7,623 (7,623 ) — Non-compete 1,010 (491 ) 519 Total $ 58,523 $ (34,071 ) $ 24,452 Identifiable intangible assets consisted of the following as of December 31, 2021: Original Accumulated Net Book Developed technology $ 32,620 $ (17,709 ) $ 14,911 Trade names and trademarks 2,080 (1,183 ) 897 Customer relationship 10,690 (1,381 ) 9,309 Independent sales agency network 4,500 (4,500 ) — Patent 7,623 (7,623 ) — Non-compete 1,010 (454 ) 556 Total $ 58,523 $ (32,850 ) $ 25,673

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses and other current liabilities consisted of the following: March 31, December 31, Personnel costs $ 23,060 $ 26,865 Royalties 3,190 3,458 Accrued but unpaid lease obligations and interest 3,981 3,963 Other 2,188 2,303 $ 32,419 $ 36,589

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Summary of liability related to the restructuring activities	The following table provides a roll-forward of the restructuring liability. Employee Other Total Liability balance as of December 31, 2021 $ 2,517 $ 651 $ Expenses 115 149 264 Payments (2,517 ) (783 ) (3,300 ) Liability balance as of March 31, 2022 $ 115 $ 17 $ 132

Long-Term Debt Obligations (Tab

Long-Term Debt Obligations (Tables)	3 Months Ended
	Mar. 31, 2022
Long-term Debt, Unclassified [Abstract]
Schedule of long-term debt obligations	Long-term debt obligations consisted of the following: March 31, December 31, Line of credit $ — $ — Term loan 73,593 74,062 Less debt discount and debt issuance cost (598 ) (637 ) Term loan, net of debt discount, debt issuance cost $ 72,995 $ 73,425
Schedule of future payments of term loan facility	Future payments of the 2021 Credit Agreement, as of March 31, 2022, are as follows for the calendar years ending December 31: 2022 $ 2,343 2023 4,687 2024 5,625 2025 6,563 2026 54,375 Total $ 73,593

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule Of Common Stock Shares Reserved For Future Issuance	As of March 31, 2022 and December 31, 2021, the Company reserved the following shares of Class A common stock for future issuance: March 31 December 31, Shares reserved for issuance for outstanding options 7,924,792 6,596,969 Shares reserved for issuance for outstanding restricted stock units 1,496,853 764,871 Shares reserved for issuance for future grants 3,373,334 5,644,691 Total shares of authorized common stock reserved for future issuance 12,794,979 13,006,531

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of Unvested Restricted Stock Units	The activity of restricted stock units is set forth below: Number of Weighted Unvested at December 31, 2021 764,871 $ 7.52 Granted 931,431 7.59 Vested (179,714 ) 7.81 Canceled/Forfeited (19,735 ) 6.83 Unvested at March 31, 2022 1,496,853 $ 7.54
Schedule of Fair Value of Stock Options Granted to Employees and Directors	The assumptions that the Company used to determine the grant-date fair value of stock options granted during these periods were as follows, presented on a weighted-average basis: Three Months Ended March 31, 2022 2021 Risk-free interest rate 1.92 % 0.82 % Expected term (in years) 6.25 6.21 Expected volatility 50.66 % 39.30 % Expected dividend yield 0.0 % 0.0 % Exercise price $ 8.03 $ 13.54 Underlying stock price $ 7.87 $ 13.54
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity since December 31, 2021: Number of Weighted Weighted (in years) Aggregate Outstanding as of December 31, 2021 6,596,969 $ 4.10 5.20 $ 38,524 Granted 1,418,224 8.03 Exercised (86,121 ) 3.38 441 Canceled / forfeited (4,280 ) 2.69 Outstanding as of March 31, 2022 7,924,792 4.82 5.83 29,053 Options exercisable as of March 31, 2022 4,600,567 2.52 3.57 25,113 Options vested or expected to vest as of March 31, 2022 7,215,073 $ 4.44 5.50 $ 28,567

Net Income (Loss) Per Share (_2

Net Income (Loss) Per Share (EPS) (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	A reconciliation of the numerator and denomina to Three Months Ended March 31, 2022 2021 Numerator: Net Income $ 87 $ 9,943 Denominator: Weighted average common shares outstanding —basic 128,788,721 127,870,065 Dilutive effect of restricted stock units 264,075 527,658 Dilutive effect of options 3,752,358 5,054,227 Weighted-average common shares outstanding—diluted 132,805,154 133,451,950 Earnings per share—basic $ 0.00 $ 0.08 Earnings per share—diluted $ 0.00 $ 0.07

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of Accrued But Unpaid Lease Obligations	The accrued but unpaid lease obligations as well as the related interest accruals are shown below. March 31 December 31, 2022 2021 Principal portion of rent in arrears 7,246 7,246 Unpaid operating and common area maintenance costs 52 558 Total accrued but unpaid lease obligations 7,298 7,804 Accrued interest on accrued but unpaid lease obligations 1,956 1,938
Schedule of Lease Cost	The components of lease cost were as follows: Three Months Ended March 31, Classification 2022 2021 Finance lease Amortization of right-of-use COGS and SG&A $ 107 $ 299 Interest on lease liabilities Interest Expense 5 349 Total Finance lease cost 112 648 Operating lease cost COGS, R&D, SG&A 2,434 1,280 Short-term lease cost COGS, R&D, SG&A 669 715 Variable lease cost COGS, R&D, SG&A 918 1,363 Total lease cost $ 4,133 $ 4,006
Summary of Balance Sheet Information Related To Finance Leases	Supplemental balance sheet information related to finance leases was as follows: March 31, 2022 December 31, Property and equipment, gross $ 1,174 $ 1,174 Accumulated depreciation (1,067 ) (961 ) Property $ 107 $ 213 Finance lease obligations $ 101 $ 200
Summary of Cash Flow Information Related To Leases	Supplemental cash flow information related to leases was as follows: Three Months Ended March 31, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 2,337 $ 1,362 Operating cash flows for finance leases $ 5 $ 523 Financing cash flows for finance leases $ 99 $ 675 Right-of-use Operating leases $ 171 $ 310 Finance leases $ — $ — March 31, December 31, Weighted-average remaining lease term Finance leases 0.21 0.45 Operating leases 8.04 8.22 March 31, December 31, Weighted-average discount rate Finance leases 11.30 % 11.30 % Operating leases 4.53 % 4.51 %
Summary of Maturities of Lease Liabilities	As of March 31, 2021, maturities of lease liabilities were as follows: Operating leases Finance leases 2022 $ 11,873 $ 103 2023 8,104 — 2024 7,315 — 2025 7,526 — 2026 7,435 — Thereafter 25,966 — Total lease payments 68,219 103 Less: interest (11,121 ) (2 ) Total lease liabilities $ 57,098 $ 101

Nature of Business and Basis _2

Nature of Business and Basis of Presentation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2022Segments
Liquidity and Financial Conditions [Line Items]
Number of Operating Segments	1
Number of Reportable Segments	1

Acquisition - Additional Inform

Acquisition - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 17, 2020	Apr. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021
Business Acquisitions, Contingent Consideration Liability Noncurrent	$ 3,782		$ 0	$ 0	$ 0
CPN Biosciences, LLC
Business Acquisitions, Aggregate Consideration	19,024
Payments​ to acquire businesses gross	$ 5,820
Issuance of common stock associated with business acquisition	1,947,953
Consideration heldback	$ 1,436
Business Acquisitions, Contingent Consideration Liability Noncurrent	$ 3,782
Earnout Calculation	70.00%
CPN Biosciences, LLC | Total Consideration Including Holdback [Member]
Payments​ to acquire businesses gross	$ 6,427
CPN Biosciences, LLC | Payment Of Holdback [Member] | Subsequent Event [Member]
Payments​ to acquire businesses gross		$ 739
CPN Biosciences, LLC | Common Class A [Member] | Payment Of Holdback [Member] | Subsequent Event [Member]
Business Acquisitions, Number Of Shares Issued		203,485
Common Stock [Member] | CPN Biosciences, LLC | Total Consideration Including Holdback [Member]
Business Acquisitions, Number Of Shares Issued	2,151,438
Business Acquisitions, Equity Interests Issued And Issuable	$ 8,815

Product and Geographic Sales -

Product and Geographic Sales - Schedule of Revenue by Product Category (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total net revenue	$ 98,117	$ 102,552
Advanced Wound Care
Total net revenue	90,950	90,708
Surgical & Sports Medicine
Total net revenue	$ 7,167	$ 11,844

Product and Geographic Sales _2

Product and Geographic Sales - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Significant Accounting Policies [Line Items]
GPO Fees	$ 619	$ 700
Sales Revenue | Geographic Concentration Risk | International
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage	1.00%

Fair Value Measurement of Fin_3

Fair Value Measurement of Financial Assets and Liabilities - Fair value of the Company's Earnout liability (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Business Acquisition, Contingent Consideration [Line Items]
Change in fair value	$ 0	$ (296)
Fair Value, Inputs, Level 3 | Earnout Liability [Member]
Business Acquisition, Contingent Consideration [Line Items]
Beginning balance	0	3,985
Change in fair value	0	(296)
Ending balance	$ 0	$ 3,689

Fair Value Measurement of Fin_4

Fair Value Measurement of Financial Assets and Liabilities - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Sep. 17, 2020
Earnout liability	$ 0	$ 0	$ 0	$ 3,782

Accounts Receivable, Net - Summ

Accounts Receivable, Net - Summary of Accounts Receivable (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Receivables [Abstract]
Accounts receivable	$ 84,604	$ 87,613
Less — allowance for doubtful accounts	(5,127)	(5,153)
Accounts receivable	$ 79,477	$ 82,460

Accounts Receivable, Net - Su_2

Accounts Receivable, Net - Summary of Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Balance at beginning of period	$ 5,153	$ 2,669
Additions	40	921
Write-offs	(66)	(14)
Balance at end of period	$ 5,127	$ 3,576

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Raw materials	$ 9,524	$ 9,023
Work in process	995	991
Finished goods	12,218	15,008
Inventory	$ 22,737	$ 25,022

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Inventory reserve and obsolescence charged to cost of goods	$ 2,205	$ 2,290

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Subscriptions	$ 2,685	$ 2,745
Conferences and marketing expenses	2,060	538
Deposits	1,344	1,216
Insurance	1,001	358
Other	45	112
Prepaid Expense	$ 7,135	$ 4,969

Property and Equipment, Net (De

Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment, Gross	$ 93,738	$ 89,433
Accumulated depreciation and amortization	(59,075)	(57,729)
Property and equipment net	84,268	79,160
Leasehold improvements
Property, Plant and Equipment, Gross	33,973	30,531
Buildings
Property, Plant and Equipment, Gross	4,943	4,943
Furniture, computers and equipment
Property, Plant and Equipment, Gross	54,822	53,959
Construction in progress
Property and equipment net	$ 49,605	$ 47,456

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Depreciation expense	$ 1,347	$ 1,010

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Identifiable intangible assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Original Cost	$ 58,523	$ 58,523
Accumulated Amortization	(34,071)	(32,850)
Net Book Value	24,452	25,673
Developed technology
Original Cost	32,620	32,620
Accumulated Amortization	(18,573)	(17,709)
Net Book Value	14,047	14,911
Trade names and trademarks
Original Cost	2,080	2,080
Accumulated Amortization	(1,236)	(1,183)
Net Book Value	844	897
Customer relationships
Original Cost	10,690	10,690
Accumulated Amortization	(1,648)	(1,381)
Net Book Value	9,042	9,309
Independent sales agency network
Original Cost	4,500	4,500
Accumulated Amortization	(4,500)	(4,500)
Patent
Original Cost	7,623	7,623
Accumulated Amortization	(7,623)	(7,623)
Non-compete agreements
Original Cost	1,010	1,010
Accumulated Amortization	(491)	(454)
Net Book Value	$ 519	$ 556

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Goodwill	$ 28,772		$ 28,772
Amortization of Intangible Assets	$ 1,221	$ 1,243

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Personnel costs	$ 23,060	$ 26,865
Royalties	3,190	3,458
Accrued but unpaid lease obligations and interest	3,981	3,963
Other	2,188	2,303
Total Accrued Expenses and Other Current Liabilities	$ 32,419	$ 36,589

Restructuring - Summary of liab

Restructuring - Summary of liability related to the restructuring activities (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Restructuring Cost and Reserve [Line Items]
Liability balance as of beginning	$ 3,168
Expenses	264	$ 927
Payments	(3,300)
Liability balance as of ending	132
Employee
Restructuring Cost and Reserve [Line Items]
Liability balance as of beginning	2,517
Expenses	115
Payments	(2,517)
Liability balance as of ending	115
Other
Restructuring Cost and Reserve [Line Items]
Liability balance as of beginning	651
Expenses	149
Payments	(783)
Liability balance as of ending	$ 17

Restructuring - Additional Info

Restructuring - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)	Mar. 09, 2022USD ($)Employees	Dec. 31, 2021USD ($)	Oct. 21, 2020Employees
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 264	$ 927
Restructuring Reserve Current	132			$ 3,168
Birmingham Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost			$ 3,000
Number of employees to retention Benefits | Employees			25
Employee Cost
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	115
Employee Cost | Birmingham Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost			$ 2,000
Facility and Other
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 149
Facility and Other | Birmingham Restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost			$ 1,000
La Jolla Restructuring
Restructuring Cost and Reserve [Line Items]
Number of employees to retention Benefits | Employees					65

Long-Term Debt Obligations (Det

Long-Term Debt Obligations (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Line of credit	$ 0	$ 0
Term loan	73,593	74,062
Less debt discount and debt issuance cost	(598)	(637)
Term loan, net of debt discount and debt issuance cost	$ 72,995	$ 73,425

Long-Term Debt Obligations - Fu

Long-Term Debt Obligations - Future payments of term loan (Detail) $ in Thousands	Mar. 31, 2022USD ($)
2022	$ 2,343
2023	4,687
2024	5,625
2025	6,563
2026	54,375
Total	$ 73,593

Long-Term Debt Obligations - Ad

Long-Term Debt Obligations - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 06, 2021	Mar. 14, 2019	Mar. 31, 2022	Dec. 31, 2021
Financial covenants	Under the 2021 Credit Agreement, the Company is required to comply with certain financial covenants including the Consolidated Fixed Charge Coverage Ratio and Consolidated Total Net Leverage Ratio, tested quarterly. In addition, the Company is also required to make representations and warranties and comply with certain non-financial covenants that are customary in loan agreements of this type, including restrictions on the payment of dividends, repurchase of stock, incurrence of indebtedness, dispositions and acquisitions.
Secured debt			$ 73,593	$ 74,062
2019 Credit Agreement
Total payment	$ 70,559
Loss on the extinguishment of debt			(1,883)
2021 Credit Agreement
Debt Instrument, Description of Variable Rate Basis	For Eurodollar Loans, the interest rate is a per annum interest rate equal to LIBOR plus an Applicable Margin between 2.00% to 3.25% based on the Total Net Leverage Ratio. For ABR Loans, the interest rate is equal to (1) the highest of (a) the Wall Street Journal Prime Rate, (b) the Federal Funds Rate plus 0.50% and (c) the LIBOR rate plus 1.0%, plus (2) an Applicable Margin between 1.00% to 2.25% based on the Total Net Leverage Ratio.
2021 Credit Agreement | Maximum [Member] | Euro Dollar Loans [Member] | Applicable Margin [Member]
Debt instrument Interest and applicable margin rate percentage	3.25%
2021 Credit Agreement | Maximum [Member] | ABR Loans [Member] | Applicable Margin [Member]
Interest rate	2.25%
2021 Credit Agreement | Minimum [Member] | Euro Dollar Loans [Member] | Applicable Margin [Member]
Debt instrument Interest and applicable margin rate percentage	2.00%
2021 Credit Agreement | Minimum [Member] | ABR Loans [Member] | Applicable Margin [Member]
Interest rate	1.00%
Term Loan [Member] | 2019 Credit Agreement
Debt Instrument, Basis Spread on Variable Rate		3.75%
Additional Payment in Aggregate of the Principal Amount Percentage		6.50%
Debt instrument face amount		$ 40,000
Debt Instrument, Description of Variable Rate Basis		annum interest rate equal to the greater of 3.75% above the Wall Street Journal Prime Rate and 9.25%
Debt instrument maturity date		2024
Fixed Interest Rate		9.25%
Term Loan [Member] | 2021 Credit Agreement
Secured debt			73,593	$ 74,062
Debt Issuance Costs, Net	$ 604
Debt instrument face amount	$ 75,000
Prepayment premium percentage	1.00%
Term Loan [Member] | 2021 Credit Agreement | September 30, 2021 through and including June 30, 2022
Debt instrument quarterly installment payment to original principal amount	$ 469
Term Loan [Member] | 2021 Credit Agreement | September 30, 2022 through and including June 30, 2023
Debt instrument quarterly installment payment to original principal amount	938
Term Loan [Member] | 2021 Credit Agreement | September 30, 2023 through and including June 30, 2025
Debt instrument quarterly installment payment to original principal amount	1,406
Term Loan [Member] | 2021 Credit Agreement | September 30, 2025 and the last day of each quarter thereafter until August 6, 2026
Debt instrument quarterly installment payment to original principal amount	1,875
Revolving Credit Facility [Member] | 2019 Credit Agreement
Maximum borrowing capacity		$ 60,000
Line of credit maturity date		2024
Line of credit description of variable rate basis for advances under revolving facility		The interest rate for advances under the revolving facility was a floating per annum interest rate equal to the greater of the Wall Street Journal Prime Rate and 5.50%.
Revolving Credit Facility [Member] | 2021 Credit Agreement
Maximum borrowing capacity	$ 125,000		125,000
Debt Issuance Costs, Net			$ 1,223
Prepayment premium percentage	1.00%
Revolving Credit Facility [Member] | 2021 Credit Agreement | Maximum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.45%
Revolving Credit Facility [Member] | 2021 Credit Agreement | Minimum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%

Stockholders' Equity (Detail)

Stockholders' Equity (Detail) - shares	Mar. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Shares reserved for issuance for outstanding options	7,924,792	6,596,969
Shares reserved for issuance for outstanding restricted stock units	1,496,853	764,871
Shares reserved for issuance for future grants	3,373,334	5,644,691
Total shares of authorized common stock reserved for future issuance	12,794,979	13,006,531

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	1 Months Ended
	Mar. 24, 2019shares
Common Class A
Company issued acquisition of shares	728,548
Redeemable Common Stock | Nutech Acquisition [Member]
Company issued acquisition of shares	728,548

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Fair value of option vested	$ 1,612	$ 143
Weighted average grant-date fair value	$ 3.94	$ 5.31
Restricted Stock Units [Member]
Unrecognized stock compensation expense	$ 7,892
Share-based compensation expected to be recognized over a weighted-average period	3 years 2 months 8 days
Restricted stock units issued to employees	931,431
Option
Unrecognized stock compensation expense	$ 7,579
Share-based compensation expected to be recognized over a weighted-average period	3 years 3 months 14 days
Selling, General and Administrative Expenses
Share-based compensation expense	$ 1,303	$ 698
2003 and 2018 Stock Incentive Plan | Maximum
Stock option granted vesting period	5 years
2003 and 2018 Stock Incentive Plan | Minimum
Stock option granted vesting period	4 days
2003 and 2018 Stock Incentive Plan | Option
Stock option expiration period	10 years
Common Class A | 2018 Stock Incentive Plan
Common stock options authorized	9,198,996

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Fair Value of Stock Options Granted to Employees and Directors (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Risk-free interest rate	1.92%	0.82%
Expected term (in years)	6 years 3 months	6 years 2 months 15 days
Expected volatility	50.66%	39.30%
Expected dividend yield	0.00%	0.00%
Exercise price	$ 13.54	$ 8.03
Underlying stock price	$ 7.87	$ 13.54

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Restricted Stock Units (Detail) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at December 31, 2021 | shares	764,871
Unvested Granted | shares	931,431
Unvested Vested | shares	(179,714)
Unvested Canceled/Forfeited | shares	(19,735)
Unvested at March 31, 2022 | shares	1,496,853
Unvested at December 31, 2021 | $ / shares	$ 7.52
Unvested Granted | $ / shares	7.59
Unvested Vested | $ / shares	7.81
Unvested Canceled/Forfeited | $ / shares	6.83
Unvested at March 31, 2022 | $ / shares	$ 7.54

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Number of Shares Outstanding	6,596,969
Number of Shares Granted	1,418,224	1,037,099
Number of Shares Exercised	(86,121)
Number of Shares Canceled / forfeited	(4,280)
Number of Shares Outstanding	7,924,792		6,596,969
Number of Shares Options Exercisable	4,600,567
Number of Shares Options vested or expected to vest	7,215,073
Weighted Average Exercise Price Outstanding	$ 4.10
Weighted Average Exercise Price Granted	8.03
Weighted Average Exercise Price Exercised	3.38
Weighted Average Exercise Price Cancelled / forfeited	2.69
Weighted Average Exercise Price Outstanding	4.82		$ 4.10
Weighted Average Exercise Price Options Exercisable	2.52
Weighted Average Exercise Price Options Vested or Expected to Vest	$ 4.44
Weighted Average Remaining Contractual Term (in years) Outstanding	5 years 9 months 29 days		5 years 2 months 12 days
Weighted Average Remaining Contractual Term (in years) Options Exercisable	3 years 6 months 25 days
Weighted Average Remaining Contractual Term (in years) Options Vested or Expected to Vest	5 years 6 months
Aggregate Intrinsic Value Outstanding	$ 38,524
Aggregate Intrinsic Value Options Exercised	441
Aggregate Intrinsic Value Outstanding	29,053		$ 38,524
Aggregate Intrinsic Value Options Exercisable	25,113
Aggregate Intrinsic Value Options Vested or Expected to Vest	$ 28,567

Stock-Based Compensation - Pare

Stock-Based Compensation - Parenthetical (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Options granted	1,418,224	1,037,099

Net Income (Loss) Per Share (_3

Net Income (Loss) Per Share (EPS) - Basic and diluted net loss per share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net Income	$ 87	$ 9,943
Weighted average common shares outstanding —basic	128,788,721	127,870,065
Weighted-average common shares outstanding—diluted	132,805,154	133,451,950
Earnings (loss) per share—basic	$ 0	$ 0.08
Earnings (loss) per share—diluted	$ 0	$ 0.07
Restricted Stock Units [Member]
Dilutive effect of awards	264,075	527,658
Employee Stock Option
Dilutive effect of awards	3,752,358	5,054,227

Net Income (Loss) per Share (_4

Net Income (Loss) per Share (EPS) - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Anti-dilutive shares excluded from the diluted EPS	155,207	1,202,193

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 11, 2021	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property plant and equipment net		$ 84,268	$ 79,160
Accrued But Unpaid Lease Obligation | Principal, Interest and CAM [Member]
Accrued but unpaid lease obligations		$ 7,298	$ 7,804	$ 10,336
275 Dan Road SPE LLC [Member]
Purchase of building under the lease amount	$ 6,013
Percentage of amount required to pay for the accrued but unpaid lease obligations associated with building	50.00%
Interest on the balance of the accrued but unpaid lease obligations associated with building was reduced to annula simplete rate,Percentage		4.50%
Property plant and equipment net	$ 4,943
Fleet Lease
Lessee, operating lease, term of contract		367 days
Maximum
Lessee, operating lease, renewal term		10 years
Minimum
Lessee, operating lease, renewal term		5 years

Leases - Schedule of Accrued bu

Leases - Schedule of Accrued but Unpaid Lease Obligations (Detail) - Accrued But Unpaid Lease Obligation [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Accrued But Unpaid Lease Obligations [Line Items]
Accrued interest on accrued but unpaid lease obligations	$ 1,956	$ 1,938
Principal [Member]
Schedule Of Accrued But Unpaid Lease Obligations [Line Items]
Total accrued but unpaid lease obligations	7,246	7,246
Principal Interest and C A M [Member]
Schedule Of Accrued But Unpaid Lease Obligations [Line Items]
Total accrued but unpaid lease obligations	7,298	7,804	$ 10,336
Common Area Maintenance [Member]
Schedule Of Accrued But Unpaid Lease Obligations [Line Items]
Total accrued but unpaid lease obligations	$ 52	$ 558

Leases - Schedule of Lease Cost

Leases - Schedule of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Leases [Abstract]
Finance lease Amortization of right-of-use assets	$ 107	$ 299
Finance lease Interest on lease liabilities	5	349
Total Finance lease cost	112	648
Operating lease cost	2,434	1,280
Short-term lease cost	669	715
Variable lease cost	918	1,363
Total lease cost	$ 4,133	$ 4,006

Leases - Summary of Balance She

Leases - Summary of Balance Sheet Information Related To Finance Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Lessee Disclosure [Abstract]
Property and equipment, gross	$ 1,174	$ 1,174
Accumulated depreciation	(1,067)	(961)
Property and equipment, net	107	213
Finance lease obligations	$ 101	$ 200
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment net

Leases - Summary of Cash Flow I

Leases - Summary of Cash Flow Information Related To Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases	$ 2,337	$ 1,362
Operating cash flows for finance leases	5	523
Financing cash flows for finance leases	99	675
Right-of-use assets obtained in exchange for lease obligations
Operating leases	$ 171	$ 310
Weighted-average remaining lease term
Finance leases	2 months 15 days		5 months 12 days
Operating leases	8 years 14 days		8 years 2 months 19 days
Weighted-average discount rate
Finance leases	11.30%		11.30%
Operating leases	4.53%		4.51%

Leases - Summary of Maturities

Leases - Summary of Maturities of Lease Liabilities (Detail) $ in Thousands	Mar. 31, 2021USD ($)
Lessee Disclosure [Abstract]
2022	$ 11,873
2023	8,104
2024	7,315
2025	7,526
2026	7,435
Thereafter	25,966
Total lease payments	68,219
Less: interest	(11,121)
Total lease liabilities	57,098
2022	103
2023	0
2024	0
2025	0
2026	0
Thereafter	0
Total lease payments	103
Less: interest	(2)
Total lease liabilities	$ 101

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Accrued Legal Expenses	$ 150		$ 150
Selling, General and Administrative Expenses
Royalty Expense	1,601	$ 1,220
License Agreement University
Accrued Royalties	1,187		$ 1,187
Royalty Expense	$ 0	$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2020
Selling, General and Administrative Expenses
Related Party Transaction, Amounts of Transaction	$ 179
Option Loans
Related Parties Notes Receivable			$ 334
Proceeds from Collection of Long-term Loans to Related Parties	$ 334
Liquidity Loan [Member]
Related Parties Notes Receivable			$ 100
Maximum [Member] | Liquidity Loan and Option Loans
Interest Rate		3.86%
Minimum [Member] | Liquidity Loan and Option Loans
Interest Rate		2.30%

Taxes - Additional Information

Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Federal corporate income tax rate	21.00%
Income tax expense	$ 45	$ 200
Discreet tax expense	$ 10	$ 10